Immuron Ltd (IMRN) Cash Funds per Single Share

The cash per share chart helps evaluate the expansion strategy of Immuron Limited (IMRN) across US and Australian pharmacies through Travelan sales. Business maturity is confirmed by the expansion of antibody sales markets, although intense competition from probiotics and dietary supplements limits growth. The current value of this metric is 0.78, allowing investors to objectively measure the company's cash cushion without speculative noise.
Analytical breakdowns for Immuron Limited

For Immuron Limited (IMRN), which maintains stable over-the-counter drug sales, this indicator confirms financial stability coupled with low development costs. The metric is calculated by dividing total liquid assets by the number of shares outstanding. Monitoring cash per share allows for a real-time assessment of an investor's actual stake in cash reserves. This chart reflects the balance between capital accumulation and its efficient utilization. High liquidity levels guarantee the business is protected against market shocks.